Femoral nerve palsy in pavlik harness treatment for developmental dysplasia of the hip

M. Lucas Murnaghan, Richard H. Browne, Daniel J. Sucato, John Birch

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Transient femoral nerve palsy is a potential complication of the use of a Pavlik harness to treat developmental dysplasia of the hip. Our hypothesis was that patients who develop a femoral nerve palsy while undergoing Pavlik harness treatment for developmental dysplasia of the hip are more likely to have unsuccessful orthotic treatment and to require closed or open hip reduction. Methods: We performed a retrospective review of all patients who underwent Pavlik harness treatment for developmental dysplasia of the hip within a seventeen-year period (1992 to 2008). All cases of femoral nerve palsy were identified and reviewed. Thirty infants met the study criteria and formed the palsy group. A control group of seventy-nine infants who did not develop femoral nerve palsy during treatment was randomly selected. Results: Thirty cases of femoral nerve palsy were identified from a group of 1218 patients for an incidence of 2.5%. Eighty-seven percent of femoral nerve palsies presented within one week of application of the Pavlik harness. Femoral nerve palsy was more likely in older, larger patients in whom the developmental dysplasia of the hip was of higher severity. Patients whose femoral nerve palsy resolved within three days had a 70% chance of having successful treatment with the Pavlik harness, whereas those who had not recovered by ten days had a 70% chance of having treatment failure with the Pavlik harness. The success rate associated with treatment with a Pavlik harness was 94% in our control group and 47% in our palsy group. Conclusions: Femoral nerve palsy is an uncommon yet clinically important complication of Pavlik harness treatment for developmental dysplasia of the hip. This complication is strongly predictive of failure of treatment, and its impact is greatest when the developmental dysplasia of the hip is higher in severity. Early recognition and management of femoral nerve palsies may improve the success of treatment. Level of Evidence: Therapeutic Level III. See Instructions to Authors for a complete description of levels of evidence.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalJournal of Bone and Joint Surgery - Series A
Volume93
Issue number5
DOIs
StatePublished - Mar 2 2011

Fingerprint

Femoral Nerve
Hip Dislocation
Paralysis
Therapeutics
Treatment Failure
Control Groups
Hip

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Femoral nerve palsy in pavlik harness treatment for developmental dysplasia of the hip. / Murnaghan, M. Lucas; Browne, Richard H.; Sucato, Daniel J.; Birch, John.

In: Journal of Bone and Joint Surgery - Series A, Vol. 93, No. 5, 02.03.2011, p. 493-499.

Research output: Contribution to journalArticle

Murnaghan, M. Lucas ; Browne, Richard H. ; Sucato, Daniel J. ; Birch, John. / Femoral nerve palsy in pavlik harness treatment for developmental dysplasia of the hip. In: Journal of Bone and Joint Surgery - Series A. 2011 ; Vol. 93, No. 5. pp. 493-499.
@article{bf1dc35c86f546179d299e71f4690dd8,
title = "Femoral nerve palsy in pavlik harness treatment for developmental dysplasia of the hip",
abstract = "Background: Transient femoral nerve palsy is a potential complication of the use of a Pavlik harness to treat developmental dysplasia of the hip. Our hypothesis was that patients who develop a femoral nerve palsy while undergoing Pavlik harness treatment for developmental dysplasia of the hip are more likely to have unsuccessful orthotic treatment and to require closed or open hip reduction. Methods: We performed a retrospective review of all patients who underwent Pavlik harness treatment for developmental dysplasia of the hip within a seventeen-year period (1992 to 2008). All cases of femoral nerve palsy were identified and reviewed. Thirty infants met the study criteria and formed the palsy group. A control group of seventy-nine infants who did not develop femoral nerve palsy during treatment was randomly selected. Results: Thirty cases of femoral nerve palsy were identified from a group of 1218 patients for an incidence of 2.5{\%}. Eighty-seven percent of femoral nerve palsies presented within one week of application of the Pavlik harness. Femoral nerve palsy was more likely in older, larger patients in whom the developmental dysplasia of the hip was of higher severity. Patients whose femoral nerve palsy resolved within three days had a 70{\%} chance of having successful treatment with the Pavlik harness, whereas those who had not recovered by ten days had a 70{\%} chance of having treatment failure with the Pavlik harness. The success rate associated with treatment with a Pavlik harness was 94{\%} in our control group and 47{\%} in our palsy group. Conclusions: Femoral nerve palsy is an uncommon yet clinically important complication of Pavlik harness treatment for developmental dysplasia of the hip. This complication is strongly predictive of failure of treatment, and its impact is greatest when the developmental dysplasia of the hip is higher in severity. Early recognition and management of femoral nerve palsies may improve the success of treatment. Level of Evidence: Therapeutic Level III. See Instructions to Authors for a complete description of levels of evidence.",
author = "Murnaghan, {M. Lucas} and Browne, {Richard H.} and Sucato, {Daniel J.} and John Birch",
year = "2011",
month = "3",
day = "2",
doi = "10.2106/JBJS.J.01210",
language = "English (US)",
volume = "93",
pages = "493--499",
journal = "Journal of Bone and Joint Surgery - American Volume",
issn = "0021-9355",
publisher = "Journal of Bone and Joint Surgery Inc.",
number = "5",

}

TY - JOUR

T1 - Femoral nerve palsy in pavlik harness treatment for developmental dysplasia of the hip

AU - Murnaghan, M. Lucas

AU - Browne, Richard H.

AU - Sucato, Daniel J.

AU - Birch, John

PY - 2011/3/2

Y1 - 2011/3/2

N2 - Background: Transient femoral nerve palsy is a potential complication of the use of a Pavlik harness to treat developmental dysplasia of the hip. Our hypothesis was that patients who develop a femoral nerve palsy while undergoing Pavlik harness treatment for developmental dysplasia of the hip are more likely to have unsuccessful orthotic treatment and to require closed or open hip reduction. Methods: We performed a retrospective review of all patients who underwent Pavlik harness treatment for developmental dysplasia of the hip within a seventeen-year period (1992 to 2008). All cases of femoral nerve palsy were identified and reviewed. Thirty infants met the study criteria and formed the palsy group. A control group of seventy-nine infants who did not develop femoral nerve palsy during treatment was randomly selected. Results: Thirty cases of femoral nerve palsy were identified from a group of 1218 patients for an incidence of 2.5%. Eighty-seven percent of femoral nerve palsies presented within one week of application of the Pavlik harness. Femoral nerve palsy was more likely in older, larger patients in whom the developmental dysplasia of the hip was of higher severity. Patients whose femoral nerve palsy resolved within three days had a 70% chance of having successful treatment with the Pavlik harness, whereas those who had not recovered by ten days had a 70% chance of having treatment failure with the Pavlik harness. The success rate associated with treatment with a Pavlik harness was 94% in our control group and 47% in our palsy group. Conclusions: Femoral nerve palsy is an uncommon yet clinically important complication of Pavlik harness treatment for developmental dysplasia of the hip. This complication is strongly predictive of failure of treatment, and its impact is greatest when the developmental dysplasia of the hip is higher in severity. Early recognition and management of femoral nerve palsies may improve the success of treatment. Level of Evidence: Therapeutic Level III. See Instructions to Authors for a complete description of levels of evidence.

AB - Background: Transient femoral nerve palsy is a potential complication of the use of a Pavlik harness to treat developmental dysplasia of the hip. Our hypothesis was that patients who develop a femoral nerve palsy while undergoing Pavlik harness treatment for developmental dysplasia of the hip are more likely to have unsuccessful orthotic treatment and to require closed or open hip reduction. Methods: We performed a retrospective review of all patients who underwent Pavlik harness treatment for developmental dysplasia of the hip within a seventeen-year period (1992 to 2008). All cases of femoral nerve palsy were identified and reviewed. Thirty infants met the study criteria and formed the palsy group. A control group of seventy-nine infants who did not develop femoral nerve palsy during treatment was randomly selected. Results: Thirty cases of femoral nerve palsy were identified from a group of 1218 patients for an incidence of 2.5%. Eighty-seven percent of femoral nerve palsies presented within one week of application of the Pavlik harness. Femoral nerve palsy was more likely in older, larger patients in whom the developmental dysplasia of the hip was of higher severity. Patients whose femoral nerve palsy resolved within three days had a 70% chance of having successful treatment with the Pavlik harness, whereas those who had not recovered by ten days had a 70% chance of having treatment failure with the Pavlik harness. The success rate associated with treatment with a Pavlik harness was 94% in our control group and 47% in our palsy group. Conclusions: Femoral nerve palsy is an uncommon yet clinically important complication of Pavlik harness treatment for developmental dysplasia of the hip. This complication is strongly predictive of failure of treatment, and its impact is greatest when the developmental dysplasia of the hip is higher in severity. Early recognition and management of femoral nerve palsies may improve the success of treatment. Level of Evidence: Therapeutic Level III. See Instructions to Authors for a complete description of levels of evidence.

UR - http://www.scopus.com/inward/record.url?scp=79952374073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952374073&partnerID=8YFLogxK

U2 - 10.2106/JBJS.J.01210

DO - 10.2106/JBJS.J.01210

M3 - Article

C2 - 21368082

AN - SCOPUS:79952374073

VL - 93

SP - 493

EP - 499

JO - Journal of Bone and Joint Surgery - American Volume

JF - Journal of Bone and Joint Surgery - American Volume

SN - 0021-9355

IS - 5

ER -